SUMMARY Burn injuries are among the most devastating of all injuries and are the fourth most common type of trauma worldwide. In the United States, there are 1.1 million burn injuries which require medical attention each year. These injuries often result in significant scarring having a negative impact on the… Read More
SUMMARY Toll-like receptor (TLR) agonists are considered promising alternatives for the estimated 50 – 75% of all cancer patients who are non-responsive to checkpoint inhibitors, and immune activation is enhanced upon stimulation of two distinct TLRs. However, the use of multiple TLR agonists as an effective therapeutic strategy is presently… Read More
SUMMARY The development of cancer immunotherapies is limited by a lack of targetable tumor antigens. Most currently targeted antigens have basal expression in healthy tissue, which results in potentially life threatening off-target effects. Moreover, targeting a single antigen alone can lead to the development of therapeutic resistance. A COSMC loss-of-function… Read More
SUMMARY IL13Ra2 is a cancer testis antigen that is expressed in 50-80% of glioblastoma cells, has no basal expression in the healthy tissue, and is correlated with poor patient prognosis. Problematically, all attempts to target this antigen therapeutically have been with IL13-mutant CAR-T cells that have significant off-target binding to… Read More